Topics

FDA Grants Priority Review to Ripretinib for Advanced Gastrointestinal Stromal Tumors

19:00 EST 12 Feb 2020 | Cancer Networks

The FDA granted a priority review to Deciphera Pharmaceuticals’ new drug application for ripretinib to treat patients with advanced gastrointestinal stromal tumors.

Original Article: FDA Grants Priority Review to Ripretinib for Advanced Gastrointestinal Stromal Tumors

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Ripretinib for Advanced Gastrointestinal Stromal Tumors"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...